Clinical trial
A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
NCT05570058 is registered in ClinicalTrials.gov with Redx Pharma Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Redx Pharma Ltd
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 8, 2022
- Completion date
- January 9, 2025
- Enrollment
- 48 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.
fibrosis, ipf